Back To Top

You have matched to 1 trial

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
Why register? Save your profile, save trials, and enter treatment history for more accurate matching.
1

Immunotherapy Mitazalimab Before Surgery in People with Breast Cancer

Window of Opportunity Study of Intratumoral CD40 Agonist (Mitazalimab) With or Without PD-1 Inhibitor (Nivolumab) in Patients With Resectable Breast Cancer (WINIT-BC)

Purpose: To study the safety and effects (good and bad) of giving the immunotherapy Mitazalimab alone or in combination with another immunotherapy Nivolumab (Opdivo®).

Who is this for?: People with stage I or stage II or stage III breast cancer who have not yet received treatment and are planning to be treated with surgery first. View full eligibility criteria

What's involved?


What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Immunotherapy may help the body's immune system attack cancer and may reduce the ability of tumor cells to grow and spread.</li> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®) is an immunotherapy that acts as a checkpoint inhibitor, blocking the PD-1 protein on immune cells to help the body's immune system recognize and destroy cancer cells.</li> <li class="seamTextUnorderedListItem">In this study, Mitazalimab may be given by itself or together with another immunotherapy Nivolumab (Opdivo®) PD-1 inhibitor to see if using these two approaches together can create a stronger immune response than using one alone.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07319195' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.opdivo.com/how-this-treatment-works?cid=sem_3436079&gclsrc=aw.ds&gad_source=1&gad_campaignid=23379047221&gbraid=0AAAAA9r9NgfsXdEH8FmLMv2kzT9JnE_yA&gclid=EAIaIQobChMI6s78s6LslAMVLYjCCB264yyPEAAYAiAAEgKPmvD_BwE' target='_blank'>Patients: See how OPDIVO helps your immune system fight cancer</a> </li></ul>
1

Immunotherapy Mitazalimab Before Surgery in People with Breast Cancer

Window of Opportunity Study of Intratumoral CD40 Agonist (Mitazalimab) With or Without PD-1 Inhibitor (Nivolumab) in Patients With Resectable Breast Cancer (WINIT-BC)
Icon

Nearest Location from 94107:
2517 miles
Hospital of the University of Pennsylvania
Philadelphia, PA

Icon

Visits:
1 visit, up to 5 years

Icon

ClinicalTrials.gov: NCT07319195

Icon

Phase I